Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells

Alice Y S Law1, Keng P Lai, Carman K M Ip

  • 1Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong.

Insights

Mammalian stanniocalcin-2 (STC2) gene expression is silenced in human cancers due to promoter hypermethylation. Reactivating STC2 via DNA demethylation restores its expression and may impact cancer progression.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Epigenetics

Background:

  • Mammalian stanniocalcin-2 (STC2) is a secreted glycoprotein hormone.
  • STC2 is implicated in the unfolded protein response and apoptosis.
  • Aberrant gene expression is a hallmark of cancer.

Purpose of the Study:

  • To investigate the epigenetic regulation of STC2 in human cancer cells.
  • To determine the role of DNA methylation in STC2 gene silencing.
  • To explore the relationship between STC2 expression, DNA methylation, and hypoxia-inducible factor 1 (HIF-1).

Main Methods:

  • Bisulfite sequencing to analyze STC2 promoter methylation.
  • Treatment with DNA methylation inhibitors (5-aza-CdR, hydralazine).
  • RNA interference and chromatin immunoprecipitation (ChIP) assays.

Main Results:

  • STC2 promoter hypermethylation and transcriptional silencing were observed in multiple human cancer cell lines.
  • DNA demethylation using 5-aza-CdR or hydralazine induced STC2 expression.
  • Normal ovarian cells exhibited low STC2 promoter methylation and high STC2 expression.
  • DNA methylation inhibited HIF-1 mediated activation of STC2 expression.

Conclusions:

  • STC2 undergoes aberrant hypermethylation in human cancers, leading to epigenetic inactivation.
  • Demethylation therapies can restore STC2 expression.
  • Epigenetic silencing of STC2 may interfere with HIF-1 mediated gene activation in cancer.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...